Response to second-line hormone treatment for advanced breast cancer. Predictive value of ploidy determination

Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer

BACKGROUND Endocrine therapy was recommended as the preferred first-line treatment for hormone receptor-positive (HR+, i.e., ER+ and/or PgR+), human epidermal growth factor receptor-2-negative (HER2-) postmenopausal advanced breast cancer (ABC), but which endocrine monotherapy is optimal lacks consensus. We aimed to identify the optimal endocrine monotherapy with a network meta-analysis. METH...

Second-line or subsequent treatment of advanced ovarian cancer

Immunotherapy for Breast Cancer Treatment

Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...

Treatment of metastatic breast cancer: second line and beyond.

Increasing use of standard chemotherapy, especially anthracycline- and taxane-based therapies, in early-stage breast cancer has led to a corresponding increase in heavily pretreated and/or treatment-resistant cases of metastatic breast cancer (MBC). Thus, second and later lines of MBC therapy frequently involve the clinically challenging picture of progressive disease and limited treatment opti...

First-Line Chemotherapy for Advanced Breast Cancer.

First-line chemotherapy for metastatic breast cancer has been the focus of ongoing controversy, a condition that partially reflects the imperfections of available therapy. It also partially reflects not only the imperfections in our ability to monitor response, but also the disagreements among clinicians over the goals of therapy. Each physician maintains a hierarchy of goals for the treatment ...